Idogen: A Cell Therapy Case Valued at a Discount - Redeye

Redeye returns with an updated assessment of Idogen following the advancement of its lead project IDO 8 and the forthcoming start of its clinical phase l/lla trial. We emphasize that the share price stands in contrast to this, currently trading at a single-digit enterprise value, offering an upside opportunity.

Länk till analysen i sin helhet: https://www.redeye.se/research/854707/idogen-a-bet-on-an-innovative-technology?utm_source=finwire&utm_medium=RSS